Clinical Trial Update: A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of upadacitinib in moderately to severely active Crohn's disease after inadequate response or intolerance to convent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-11-23